<?xml version="1.0" encoding="UTF-8"?>
<p>After over 5 years of debate and negotiations with pressure from the governments of mainly in developing countries and nongovernmental organizations, a consensus was reached. The Doha Declaration on the TRIPS Agreement and Public Health (simply referred to as the “Doha Declaration”) was adopted in November of [
 <xref ref-type="bibr" rid="CR5">5</xref>]. It states that the “TRIPS Agreement does not and should not prevent Members from taking measures to protect public health. Accordingly, while reiterating our commitment to the TRIPS Agreement, we affirm that the Agreement can and should be interpreted and implemented in a manner supportive of WTO members’ rights to protect public health and, in particular, to promote access to medicines for all” [
 <xref ref-type="bibr" rid="CR6">6</xref>]. Therefore, the Doha Declaration reaffirms the right of WTO member states to grant compulsory licenses in a state of national emergency. Compulsory licensing refers to a government’s consent to someone other than the patent owner to produce the patented product or process without the consent of the patent owner. Specifically in the medical field, the term denotes the government allowing a third party to produce patented drugs. However, TRIPS mandates that the drugs produced under a compulsory license must be used only in the domestic market, which creates a major obstacle for the countries with no manufacturing capacity in the pharmaceutical sector to import unregistered generic drugs [
 <xref ref-type="bibr" rid="CR6">6</xref>].
</p>
